Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392346 | 0.88 | MMP13 (0.48) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL7105028 | 0.88 | MMP13 (0.59) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL6247398 | 0.87 | MMP13 (0.64) | PARGHDAC1MMP13SLC22A8MAPK8 | |
| SCHEMBL27588029 | 0.85 | PARG (0.52) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL7103213 | 0.84 | PARG (0.52) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL27588034 | 0.84 | PARG (0.52) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL7634243 | 0.84 | TP53 (0.57) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL27588009 | 0.84 | PARG (0.54) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL27588021 | 0.84 | PARG (0.54) | PARGHDAC1MMP13SLC22A8TP53 | |
| SCHEMBL6245488 | 0.84 | MMP13 (0.60) | PARGHDAC1MMP13SLC22A8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | disclosed |
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | WARNER-LAMBERT COMPANY LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004014381-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC. (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | MMP13, MMP3, MMP26 | PARG 4062/4885HDAC1 153/4885MMP13 1/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | PARG 4866/4885HDAC1 370/4885MMP13 1/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | PARG 4840/4885HDAC1 205/4885MMP13 1/4885 |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | PARG 4006/4885HDAC1 1073/4885MMP13 1/4885 |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | PARG 4518/4885HDAC1 862/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.